Evidence map›Paper›PMID 26490187›Full record

ArticleJournal of human genetics2016

Tumor-suppressive microRNAs (miR-26a/b, miR-29a/b/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma.

Ichiro Fukumoto, Naoko Kikkawa, Ryosuke Matsushita, Mayuko Kato, Akira Kurozumi, Rika Nishikawa, Yusuke Goto, Keiichi Koshizuka, Toyoyuki Hanazawa, Hideki Enokida and 3 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Journal of human genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.Medical oncology (Northwood, London, England) · 2024
    Review
  6. Analysis of miRNAs inPharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. LOXL2 in Cancer: A Two-Decade Perspective.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Comparison of miRNA expressions among benign, premalignant and malignant lesions of the larynx: could they be transformation biomarkers?Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2021
    Article
  16. Article
  17. Review
  18. Down-Regulation ofFrontiers in oncology · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ichiro FukumotoDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Naoko KikkawaDepartment of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Ryosuke MatsushitaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Mayuko KatoDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Akira KurozumiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Rika NishikawaDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Yusuke GotoDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Keiichi KoshizukaDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Toyoyuki HanazawaDepartment of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Hideki EnokidaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Masayuki NakagawaDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Yoshitaka OkamotoDepartment of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Naohiko SekiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Chiba University · JPKagoshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In spite of considerable advances in multimodality therapy, including surgery, radiotherapy and chemotherapy, the overall survival rate for patients with head and neck squamous cell carcinoma (HNSCC) is very poor (only 15-45%). Understanding the molecular mechanisms of metastatic pathways underlying HNSCC using currently available genomic approaches might improve therapies for and prevention of the disease. Our previous studies showed that three tumor-suppressive microRNAs (miRNAs), miR-26a/b, miR-29a/b/c and miR-218, significantly inhibited cancer cell migration and invasion. Therefore, we hypothesized that these miRNAs-regulated target genes deeply contributed to cancer metastasis. These tumor-suppressive miRNAs directly regulate LOXL2 expression in HNSCC cells by using in silico analysis and luciferase reporter assays. Overexpressed LOXL2 was confirmed in HNSCC clinical specimens, and silencing of LOXL2 inhibited cancer cell migration and invasion in HNSCC cell lines. Our present data showed that tumor-suppressive miRNAs regulation of LOXL2 will provide new insights into the novel molecular mechanisms of HNSCC metastasis.

Indexed as

Gene Expression Regulation, NeoplasticAmino Acid OxidoreductasesCarcinoma, Squamous CellCell Line, TumorCell MovementCell ProliferationHead and Neck NeoplasmsHumansMicroRNAsSquamous Cell Carcinoma of Head and NeckAmino Acid OxidoreductasesLOXL2 protein, humanMicroRNAsMIRN218 microRNA, humanMIRN26 microRNA, humanMIRN29a microRNA, human

Identifiers

PMID26490187
OpenAlexW2219177006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.